Evaluating a New Drug to Combat Fentanyl Effects
Author Information
Author(s): Malfatti Michael A., Enright Heather A., McCloy Summer, Ubick Esther A., Kuhn Edward, Subramanian Alagu, Lao Victoria Hio Leong, Lam Doris, Be Nicholas A., Hok Saphon, Lau Edmond Y., Kaseman Derrick C., Mayer Brian P., Valdez Carlos A.
Primary Institution: Lawrence Livermore National Laboratory
Hypothesis
Can Subetadex-α-methyl effectively neutralize the effects of fentanyl and related opioids?
Conclusion
Subetadex-α-methyl shows promise as a medical countermeasure against fentanyl and its analogs by reducing recovery times in rats.
Supporting Evidence
- SBX-Me reduced recovery times from ∼35 to ∼17 min for fentanyl.
- SBX-Me reduced recovery times from ∼172 to ∼59 min for carfentanil.
- SBX-Me reduced recovery times from ∼18 to ∼12 min for remifentanil.
- SBX-Me has a nontoxic profile comparable to Sugammadex.
- Pharmacokinetic analysis showed rapid clearance of SBX-Me with an elimination half-life of ∼7.4 h.
Takeaway
A new drug called Subetadex-α-methyl can help people recover faster from fentanyl and similar drugs.
Methodology
The study involved in vitro toxicity assays and pharmacokinetic analysis in rats to evaluate the effectiveness of SBX-Me against fentanyl.
Limitations
The study was conducted in rats, and further research is needed to confirm results in humans.
Participant Demographics
Male Sprague–Dawley rats weighing 250–300 g were used in the study.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website